About: Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 2008

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2008 (uk) im Mai 2008 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en mayu de 2008 (ast) scientific article published on 01 May 2008 (en)
publication date	wds:Q81158279-96E42A90-24E1-4F0C-B46D-A1B3A740B0B0
publication date	2008-05-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q81158279-0A8C0B60-09B4-4602-B4D9-9945E1E9AADA wds:Q81158279-43D8B7AD-EED3-4034-9A83-28809252B1B4 wds:Q81158279-481267BF-710B-44BD-BD58-121E2930C2ED wds:Q81158279-584A5F18-C9CA-423F-AE8E-FC3E13A5A053 wds:Q81158279-640FEF6C-E0D7-46D0-973B-D23557EA4D1F wds:Q81158279-65748C3B-87CC-415E-B277-64F9B8541B4E wds:Q81158279-8272E509-2118-44EC-9DBA-753BE4CC0E24 wds:Q81158279-8D1DE252-2DE8-4B7F-AE1E-0982C9E0E823 wds:Q81158279-D875BCD7-65EC-4EA1-92AF-30799F01364E wds:Q81158279-F7AD27B7-BAAB-4CDE-BDD3-B4035294D1C5
author name string	Takahiko Horiuchi Mine Harada Hiroki Mitoma Hiroshi Tsukamoto Yasutaka Kimoto Ayumi Uchino Shin-ichi Harashima Kentaro To Yasuhiro Tamimoto Nobuaki Hatta
rdfs:label	Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab (en) Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab (nl)
skos:prefLabel	Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab (en) Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab (nl)
name	Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab (en) Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab (nl)
title	wds:Q81158279-13189FFA-736E-4B44-A332-7F5C40C66F52
title	Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab (en)
page(s)	wds:Q81158279-32444A0A-1AD8-4D62-80F1-6B29FEB1AEE4
page(s)	1248-1257
instance of	wds:Q81158279-FCB99B99-1E05-42DA-9757-8B3DB3987081
instance of	scholarly article
main subject	wds:Q81158279-CBB0AC5D-FC57-405E-8B61-73C1D83313BE
main subject	adalimumab
PubMed ID	wds:Q81158279-048C7976-575B-4209-AFF5-C3AA638F4A5B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18438840
PubMed ID	18438840
published in	wds:Q81158279-8A2E2888-DAF4-4201-A21A-15978DD2EC90
published in	Arthritis and Rheumatism
issue	wds:Q81158279-0667E308-2998-4CFC-9803-D98E0F588528
volume	wds:Q81158279-EFBE4C31-525C-4E01-B34E-EF60FA1A10F1
issue	5
volume	58
DOI	wds:Q81158279-48620825-404F-416F-8EBC-EFC5DEEE35EE
DOI	http://dx.doi.org/10.1002/ART.23447
DOI	10.1002/ART.23447
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q81158279
is cites work of	Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability Survival dimensionality reduction (SDR): development and clinical application of an innovative approach to detect epistasis in presence of right-censored data FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry TNF Accelerates Death of Mandibular Condyle Chondrocytes in Rats with Biomechanical Stimulation-Induced Temporomandibular Joint Disease Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions Acute graft-versus-host disease: new treatment strategies Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study How tumour necrosis factor blockers interfere with tuberculosis immunity. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study TNF-alpha and its inhibitors in cancer Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-alpha co-expression, but little interleukin-22 and interleukin-23R expression Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report Fc gamma receptor CD64 modulates the inhibitory activity of infliximab Exome sequencing reveals RAG1 mutations in a child with autoimmunity and sterile chronic multifocal osteomyelitis evolving into disseminated granulomatous disease Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed Complement-targeted therapy: development of C5- and C5a-targeted inhibition. Cellular and humoral mechanisms involved in the control of tuberculosis Novel mechanisms of action of the biologicals in rheumatic diseases. Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices Development of Diagnostic Techniques for Early Rheumatoid Arthritis Using Positron Emission Tomography with [11C]PK11195 and [11C]Ketoprofen Tracers The Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid Arthritis TNF Blockade Maintains an IL-10+ Phenotype in Human Effector CD4+ and CD8+ T Cells Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease A patient with urinary tract tuberculosis during treatment with etanercept Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept Caspase-8: not so silently deadly Anti-TNF-alpha therapy and systemic vasculitis T0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFα Humanization and characterization of an anti-human TNF-α murine monoclonal antibody Tumor necrosis factor inhibitors - state of knowledge Identification of HLA-DRB1 association to adalimumab immunogenicity.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software